Literature DB >> 25581537

Organ-sparing surgery in urology: partial cystectomy.

John Knoedler1, Igor Frank.   

Abstract

PURPOSE OF REVIEW: While radical cystectomy continues to be the gold standard for surgical management of muscle invasive bladder cancer, there has been a renewed interest in partial cystectomy as a viable treatment alternative. The purpose of this review is to summarize and discuss the recent literature regarding partial cystectomy for bladder cancer. RECENT
FINDINGS: Utilization of partial cystectomy has remained stable, at a rate of 7-10% of all cystectomies performed nationally. Additionally, recent population-based series as well as single institution cohorts have found that partial cystectomy did not compromise survival when compared to radical cystectomy. While patients may recur, those with organ-confined disease had no difference in survival following salvage cystectomy when compared to primary radical cystectomy. Current data indicate 14% of patients experience an in-hospital complication, which is a marked decrease compared to radical cystectomy. Finally, innovations in surgical technique, such as robotics, as well as the inclusion of partial cystectomy into trimodal therapy, offer exciting new frontiers in bladder cancer treatment.
SUMMARY: Once maligned, partial cystectomy now represents a standard-of-care option for management of bladder cancer. Although additional research is needed to clarify patient selection and outcomes, partial cystectomy is an important treatment option for appropriately selected patients.

Entities:  

Mesh:

Year:  2015        PMID: 25581537     DOI: 10.1097/MOU.0000000000000145

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  13 in total

1.  Impact of Surgical Technique on Surgical Margin Status Following Partial Cystectomy.

Authors:  Michael Owyong; Tulay Koru-Sengul; Feng Miao; Shirin Razdan; Kevin J Moore; Mahmoud Alameddine; Sanoj Punnen; Dipen J Parekh; Chad R Ritch; Mark L Gonzalgo
Journal:  Urol Oncol       Date:  2019-08-21       Impact factor: 3.498

2.  Partial cystectomy for urothelial carcinoma of the bladder: Practice patterns and outcomes in the general population.

Authors:  Michael J Leveridge; D Robert Siemens; Jason P Izard; Xuejiao Wei; Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2017-11-01       Impact factor: 1.862

3.  Robotic-assisted laparoscopic partial cystectomy for symptomatic urachal hamartoma.

Authors:  Richard Shepler; Jack M Zuckerman; Dean Troyer; John B Malcolm
Journal:  Turk J Urol       Date:  2016-03

4.  Clinical behavior and survival outcome of urothelial bladder cancer in young adults.

Authors:  Shahbaz Mehmood; Khalid Ibraheem Alothman; Majed Al Rumayyan; Waleed Mohammed Altaweel; Turki Omar Alhussain
Journal:  Urol Ann       Date:  2022-04-18

Review 5.  [Organ-sparing treatment of bladder cancer].

Authors:  C Niedworok; A Shaleva; H Rübben; A Stenzl
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

6.  Urothelial carcinoma management in elderly or unfit patients.

Authors:  Joaquim Bellmunt; Nicolas Mottet; Maria De Santis
Journal:  EJC Suppl       Date:  2016-03-22

7.  Deceptive muscle invasive bladder cancer recurrence with benign biopsy foci after bladder sparing treatment.

Authors:  Chuanliang Xu; Shuxiong Zeng; Zhensheng Zhang; Ruixiang Song; Chong Ma; Xin Chen; Yinghao Sun
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

8.  Effects of microRNA-135a on the epithelial-mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3β through the Wnt/β-catenin signaling pathway.

Authors:  Xia-Wa Mao; Jia-Quan Xiao; Zhong-Yi Li; Yi-Chun Zheng; Nan Zhang
Journal:  Exp Mol Med       Date:  2018-01-19       Impact factor: 8.718

9.  Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer.

Authors:  Jan Ebbing; Robin Colja Heckmann; Justin William Collins; Kurt Miller; Barbara Erber; Frank Friedersdorff; Tom Florian Fuller; Jonas Busch; Hans Helge Seifert; Peter Ardelt; Christian Wetterauer; Abolfazl Hosseini; Florian Jentzmik; Carsten Kempkensteffen
Journal:  Sci Rep       Date:  2018-05-30       Impact factor: 4.379

Review 10.  Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?

Authors:  Boris Gershman; Stephen A Boorjian; Richard E Hautmann
Journal:  Bladder Cancer       Date:  2015-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.